Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2007

Vion Extends Manufacturing Agreement with SAFC

  • Vion Pharmaceuticals extended its manufacturing agreement with SAFC for its lead anticancer agent, Cloretazine®, to September 2009. SAFC will continue to manufacture Cloretazine active pharmaceutical ingredient (API).

    In December 2006, Vion entered into a manufacturing agreement for Cloretazine finished drug product with Ben Venue Laboratories. Ben Venue will manufacture Cloretazine finished drug product using API manufactured by SAFC.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »